Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B7-H3-SDIE
- Development stage
- Preclinical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
B7-H3-SDIE is an Fc-modified monoclonal antibody designed for the treatment of pancreatic cancer. It targets the antigen B7-H3 (CD276), which is highly expressed in many tumor entities, including pancreatic cancer, with limited expression on healthy tissues. The antibody features amino acid substitutions S239D/I332E in its Fc region, which are engineered to increase its affinity for the Fc receptor CD16 expressed on natural killer (NK) cells. This modification enhances antibody-dependent cellular cytotoxicity (ADCC), leading to effective activation of NK cells against pancreatic cancer cells, resulting in significant tumor cell lysis.
02
Targets
B7-H3FCGR3B (Fc gamma receptor III)
Beyond the preview
Go deeper on B7-H3-SDIE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B7-H3-SDIE.